# A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

> **NCT06072586** · EARLY_PHASE1 · RECRUITING · sponsor: **St. Joseph's Hospital and Medical Center, Phoenix** · enrollment: 82 (estimated)

## Conditions studied

- High Grade Glioma
- Glioblastoma

## Interventions

- **DRUG:** BDTX-1535
- **DRUG:** BDTX-1535 combined with radiation therapy
- **DRUG:** BDTX-1535 combined with temozolomide and radiation therapy

## Key facts

- **NCT ID:** NCT06072586
- **Lead sponsor:** St. Joseph's Hospital and Medical Center, Phoenix
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072586, "A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06072586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*